Search results
Meta-analysis of the studies assessing the relation between HIV infection and OSSN. * indicates that this RR estimate was computed by the authors of the present meta-analysis with data provided in the original report although the controls were frequency age- and sex-matched with the cases; a sensitivity analysis excluding this study yielded a summary RR of 9.1 (95% CI: 6.1–13.6, I 2 =43.8% ...
5 cze 2018 · Both the pooled crude RR and adjusted aRR suggested a statistically significant increased risk of acquisition of HPV (pooled RR = 1.55, 95% CI: 1.29 to 1.88; pooled aRR = 2.46, 95% CI: 1.86 to 3.26), HR‐HPV (pooled RR = 2.20, 95% CI: 1.90 to 2.54; pooled aRR = 1.87, 95% CI: 1.32 to 2.67) and HPV‐16 (pooled RR 2.10, 95% CI: 1.63 to 2.67 ...
17 lut 2023 · HPV and HIV are different sexually transmitted infections caused by viruses. A person with HIV may be more prone to contracting HPV and experience worse complications. Learn more here.
1 paź 2013 · Abstract. Background: The frequency of ocular surface squamous neoplasias (OSSNs) has been increasing in populations with a high prevalence of infection with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and infection with human papillomavirus (HPV).
1 lip 2007 · Clinicians should be aware of the most important changes in ocular complications of HIV/AIDS in the era of HAART: decreased but still significant risk of cytomegalovirus (CMV) retinitis; immune-recovery uveitis; and possible discontinuation of anti-CMV therapy in patients with immune recovery.
These results provide evidence for synergistic HIV and HPV interactions of clinical and public health relevance. HPV vaccination may directly benefit PLHIV, and help control both HPV and HIV at the population level in high prevalence settings.
Herein, the main epidemiological features and clinical implications of HIV and HPV coinfection are reviewed, focusing mainly on the relationship between HIV immune status and HPV-related diseases and the current strategies used to reduce the burden of HPV-related disease.
